First Author: N.I.Ucgun TURKEY
Co Author(s): A. Uysal M. Onen Z. Yazar H. Sarikatipoglu 0 0 0 0 0 0 0 0 0
Back to previous
The aim of this study is to evaluate the efficacy of intravitreal (IV) bevacizumab and ranibizumab application for the management of diabetic macular edema (DME).
Ankara Numune Education and Research Hospital
A total number of 139 eyes of 98 patients with DME were included in the study who were treated and followed up for 24 weeks. 45 eyes of 35 patients were treated with 0.5 mg (0.05 ml) IV ranibizumab (group 1) and 94 eyes of 63 patients were treated with 1.5 mg (0.06 ml) IV bevacizumab (group 2). Patients were compared between before and after treatment in terms of best corrected visual acuity and central macular thickness values. The patients comprised 45 females (45,92 %) and 53 males (54,08 %) who were included in the study. The mean age was 57.62 ± 8.12 in group 1 and 58.85 ± 6.93 in group 2. There was no statistically significant difference between the two groups in terms of sex and age distribution. The mean number of injections was 3.28 ± 0.45 in group 1 and 3.55 ± 0.49 in group 2. The patients who had HbA1c levels less than 10 % were included in the study.
In group 1, mean best corrected visual acuity (BCVA) (logMAR) was 0,74 ± 0,47 before treatment and 0,57 ± 0,38 after treatment. In group 2, mean best corrected visual acuity (BCVA) (logMAR) was 0.82 ± 0.50 before treatment and 0.64 ± 0.41 after treatment. Both in Group 1 and 2, when we compared best corrected visual acuity before and after treatment, it was observed a statistically significant increase (p=0,00). In group 1, mean central macular thickness was 477.34 ± 125.80 μm before treatment and 366.17 ± 156.03 μm after treatment. In group 2, mean central macular thickness was 440,09 ± 109,08 μm before treatment and 341,60 ± 113,11 μm after treatment. Both in Group 1 and 2, when we compared central macular thickness before and after treatment, it was observed a statistically significant reduction (p=0,00). When groups 1 and 2 were compared with each other in terms of the best corrected visual acuity before and after treatment and central macular thickness before and after treatment, no statistically significant differences were found
IV bevacizumab and IV ranibizumab are associated with similar effects on central macular thickness in patients with DME. Ranibizumab is an original and safe molecule that is produced for the eye. The safety of bevacizumab remains the greatest element of uncertainty. For this reason, although expensive, ranibizumab is a molecule that can be the preferred choice.